DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Resistance to antibody–drug conjugates
Antibody–drug conjugates (ADC) are multicomponent molecules constituted by an antibody covalently linked to a potent cytotoxic agent. ADCs combine high target specificity provided by the antibody together with strong antitumoral properties provided by the attached cytotoxic agent. At present, four ADCs have been approved and over 60 are being explored in clinical trials. Despite their effectiveness, resistance to these drugs unfortunately occurs. Efforts to understand the bases underlying such resistance are being carried out with the final purpose of counteracting them. In this review, we report described mechanisms of resistance to ADCs used in the clinic along with other potential ones that may contribute to resistance acquisition. We also discuss strategies to overcome resistance to ADCs., This work was supported by the Ministry of Economy and Competitiveness of Spain (BFU2015-71371-R to A. Pandiella and BES-2013-065223 to S. GarcíaAlonso); the Junta de Castilla y Leon (CSI002U16); the Scienti fic Foundation of
the AECC and the CRIS Foundation (to A. Pandiella). Work in A. Ocana~ laboratory is supported by the Instituto de Salud Carlos III (PI16/01121); ACEPAIN; Diputacion de Albacete; and the CRIS Cancer Foundation. The work
carried out in our laboratories receives additional support from the European Community through the regional development funding program (FEDER).